On 8 October 2026, Pinnacle Marine Holdings Ltd filed for a HKEX listing with Alliance Capital Partners Limited as sole sponsor; it ranked third among Singapore aluminium workboat builders by 2025 deliveries.
On 8 October 2026, ESWIN COMPUTING (01256.HK) set its final offer price at HK$ 1.55 per H Share for 1,617,310,000 H Shares, with net proceeds of about HK$ 2,385.7 million and a listing set for 9 October.
On 8 Oct 2026, PLUS GP HOLDING (02486.HK) agreed to buy the remaining 40% of two subsidiaries from a connected person for RMB21.64m and RMB19.24m.
On 8 Oct 2026, XIN YUAN ENT (01748.HK) said ICBC International launched a conditional voluntary cash offer at HKD 2.21 per share, a 25.57% premium.
On 8 Oct 2026, SUNSHINE PHARMA (06887.HK) won NMPA approval for its insulin degludec/aspart injection, taking its approved insulin range in China to 7.
On 8 Oct 2026, SERES (09927.HK) posted September NEV sales of 29,271 units (-34.48% YoY) and output of 28,387 (-37.55%); YTD sales 256,521 (-15.79%).
On 8 Oct 2026, CSPC PHARMA (01093.HK) unveiled Phase I data for SYS6002 in cervical cancer at IGCS 2026: confirmed ORR 35.9% and 28.6%; Phase III started.
On 8 Oct 2026, GLMS SEC (01456.HK) said its controlling shareholder will add shares in 6 months, after the price fell below 80% of the RMB 11.17 issue price.
On October 8, Hong Kong stocks fell, with the HSI down 1.43%. DIAGENS-B led Stock Connect with a 21.75% rise and HK$6.477 billion of southbound net buying.
On 8 October 2026, SSY GROUP (02005.HK) said it won NMPA production approval for nimodipine oral solution (10ml:60mg) in China, a Category 3 chemical drug.
On October 8, 2026, Hong Kong stocks fell broadly, with the HSTECH down 2.89% to a new low since September 2024. MINIMAX-W slumped 13.74%; BABA-W eased 1.04%.
On 8 October 2026, TAT HONG EQUIP (02153.HK) issued its 11th SDAX digital paper series at 4.65%, expecting to raise SGD 28m to SGD 33m for working capital.
On 8 October 2026, GIGADEVICE (03986.HK) said its September buyback of 789,600 A shares lifted cumulative repurchases to 2.4519m shares, or 0.35% of capital.
On 8 October 2026, SBP GROUP (01177.HK) said the Phase III PACER-III trial of its TQC3721 inhalation suspension for COPD in China completed full enrolment.
On October 8, 2026, the Hong Kong ETF market was shaped by a defensive tilt. Dividend and high-yield plays led the advance, with the Bosera China Reform Hong Kong Central-SOEs High Dividend Yield Index ETF (Listed Class) topping the gainers at +1.40%; six of the top ten gainers were dividend or high-dividend related products. On the downside, AI, technology and semiconductor themes retreated sharply, led by the Hang Seng AI Advancement ETF at −5.76%, with every name in the top ten decliners falling at least 4.3%. Among southbound (Stock Connect) ETFs, dividend products edged higher while Hong Kong-Korea tech and biotech themes led the declines.
on October 8, 2026, the three major Hong Kong indices fluctuated and weakened, with the Hang Seng Index down 1.43%, the Hang Seng TECH Index down 2.89%, and the Hang Seng China Enterprises Index down 0.89%.
